RCT: Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer.
12 Apr, 2022 | 08:54h | UTCNeoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer – New England Journal of Medicine
News Release: Immunotherapy Plus Chemotherapy Before Surgery Improves Outcomes for Patients with Lung Cancer – Johns Hopkins Medicine
Commentary on Twitter
In patients with resectable NSCLC, neoadjuvant nivolumab plus chemo results in longer event-free survival and a greater likelihood of pathological complete response than chemo alone. #AACR22 https://t.co/ILjdRZQ7dJ pic.twitter.com/1JfiUw18R6
— NEJM (@NEJM) April 11, 2022